Company intelligence / Profile preview

PyrAmes

Cupertino, California, United Statespyrameshealth.com ↗

Ownership: Private
Employees: ~49
Development stage: Commercial

Overview

Boppli®, the company’s lead product, received FDA Breakthrough Device Designation and FDA 510(k) clearance in September 2023. It provides continuous, non-invasive blood pressure monitoring for critically ill infants as an alternative to invasive arterial lines or intermittent cuff-based measurements. Clinical studies have demonstrated its value in NICU settings. Adult and home-use products are under development.

Therapeutic areas: OtherCardiovascular
Modalities: DeviceWearable deviceDigital health technology
Industry: Physiological Monitoring

Drug pipeline

3 assets

Boppli

Commercial

Indications: Neonatal critical care blood pressure monitoring

2 more assets in the full pipeline.

Request access →

Partnerships

Sentec AG – commercial partnership to bring Boppli to U.S. NICUs

Beyond the preview

Go deeper on PyrAmes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PyrAmes.

Explore the full profile